Compare · DXCM vs STIM
DXCM vs STIM
Side-by-side comparison of DexCom Inc. (DXCM) and Neuronetics Inc. (STIM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and STIM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.65B, about 148.2x STIM ($227.1M).
- DXCM has been more active in the news (9 items in the past 4 weeks vs 7 for STIM).
- DXCM has more recent analyst coverage (25 ratings vs 5 for STIM).
- Company
- DexCom Inc.
- Neuronetics Inc.
- Price
- -
- -
- Market cap
- $33.65B
- $227.1M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2018
- News (4w)
- 9
- 7
- Recent ratings
- 25
- 5
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Neuronetics Inc.
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2003 and is headquartered in Malvern, Pennsylvania.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 101,502 units (SEC Form 4) (withholding obligation)
- EVP, Chief Financal Officer Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.96% to 150,390 units (SEC Form 4) (withholding tax)
- President, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 418,908 units (SEC Form 4) to satisfy withholding tax
- EVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 128,608 units (SEC Form 4) (withholding tax)
- Executive Chair Sayer Kevin R sold $2,408,242 worth of shares (26,756 units at $90.01) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 302,214 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $156,281 worth of shares (1,700 units at $91.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 102,953 units (SEC Form 4)
- Director Augustinos Nicholas gifted 1,075 shares (SEC Form 4)
- Director Heller Bridgette P sold $89,349 worth of shares (1,012 units at $88.29) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 29,570 units (SEC Form 4)
- Director Foletta Mark G sold $330,640 worth of shares (4,000 units at $82.66) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by DexCom Inc.
Latest STIM
- SEC Form 8-K filed by Neuronetics Inc.
- Large owner Chernett Jorey bought $44,240 worth of shares (14,000 units at $3.16), increasing direct ownership by 0.13% to 10,602,988 units (SEC Form 4)
- SEC Form S-8 filed by Neuronetics Inc.
- SEC Form 10-Q filed by Neuronetics Inc.
- Neuronetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure
- Neuronetics Reports Second Quarter 2026 Financial and Operating Results
- Neuronetics and Jorey Chernett Announce Shared Vision
- Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Greenbrook Opens National Center of Excellence for Advanced Interventional Psychiatry in Rockville, Maryland
- Neuronetics to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call